XML 17 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Common Stock) (Details) (USD $)
 1 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2012
Mar. 31, 2013
Dec. 31, 2012
Feb. 28, 2013
Jan. 31, 2014
Subsequent Event
Dec. 31, 2014
Subsequent Event
Mar. 31, 2014
Subsequent Event
Aug. 31, 2013
Subsequent Event
Sep. 30, 2012
Novosom
Jan. 31, 2012
Novosom
Mar. 31, 2013
Novosom
Dec. 31, 2013
Novosom
Subsequent Event
Dec. 31, 2012
Public Offering One
Series A Warrants
Stockholders Equity Note [Line Items]                          
Number of voting right   one Vote                      
Fair value of shares to be issued   $ 380,000         $ 1,100,000            
Number of common shares issued during period through exercise of warrants           1,200,000              
Number of warrants issued   1,000,000     100,000                
Exercise price of warrants     0.28 0.28 0.89     0.28         0.28
Value of shares issued to landlord 1,500,000                        
Amount owned from vendors     1,600,000                    
Common stock shares reserve for settlement of loan     3,900,000                    
Outstanding amount of loan from vendor     1,200,000                    
Shares issued during period for settlement of outstanding amounts due to vendors     3,800,000                    
Shares to be issued during period for settlement of outstanding amounts due to vendor   100,000                      
Value of shares issued during period for settlement of outstanding amounts due to vendors   20,000                      
Description of consideration for sub-licensed lipid-delivery technology                    
As part of the asset purchase agreement that we entered into with Novosom in July 2012, we are obligated to pay Novosom 30% of any payments received by us for sub-licensed SMARTICLES® technology. The consideration is payable in a combination of cash (no more than 50% of total due) and common stock, at our discretion.
    
Shares issued as consideration for sub-licensed lipid-delivery technology                 340,000 340,000      
Fair value of shares issued   $ 130,000             $ 110,000        
Commitment of additional issuance of shares for future   510,000             510,000 510,000   500,000  
Shares issued during the period in settlement of amounts due under employment agreement and accrued board fees           2,690,000